KMDA Overview
Upcoming Projects (KMDA)
-
2nd View: Examining Emerging Gene-editing Therapies for alpha-1 antitrypsin deficiency (AATD), including Beam Therapeutics' BEAM-302
Tickers: BEAM, TAK, GRFS, KMDA
Execute By: May 31, 2026
Executed Projects (KMDA)
-
Examining Emerging Gene-editing Therapies for alpha-1 antitrypsin deficiency (AATD), including Beam Therapeutics' BEAM-302
Tickers: BEAM, TAK, GRFS, KMDA
Executed On: Apr 22, 2026 at 10:00 AM EDT
Upcoming & Overdue Catalysts (KMDA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (KMDA)
-
KMDA's Phase 2 data for Alpha-1 Antitrypsin for Pediatric Patients newly diagnosed with Type 1 diabetes Expected Q3 2017
Ticker: KMDA
Occurred on: Jan 08, 2018 -
Kamada Meets Primary Endpoint of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of Alpha-1 Antitrypsin Deficiency
Ticker: KMDA
Occurred on: Aug 30, 2016
Strategic Initiatives (KMDA)
-
Shire (SHPG) Extends Kamada's (KMDA) GLASSIA Supply Agreement Through 2020
Tickers: KMDA, SHPG
Announcement Date: Oct 06, 2016